Eli Lilly takes further action over ‘dangerous’ diabetes drug fakes

US drugmaker files six lawsuits over compounded tirzepatide products | At least five deaths associated with ‘generic’ Mounjaro, according to complaint | Fears over drug's 'unapproved' use for cosmetic weight loss.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pharmacy defends Eli Lilly off-label drug suit

11 April 2024 Diabetes drug is known for its off-label use as a weight-loss aid | Judge censures pharma giant for using state law instead of federal law in complaint | Development follows a wave of litigation involving Mounjaro.

Big Pharma

Teva and Eli Lilly end patent clash over migraine drug

28 November 2023 Rival drugmakers have dropped lawsuit following invalidation of Teva patents in September | Move comes after judge overturned jury verdict handing $176.5m to Teva.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Eli Lilly takes further action over ‘dangerous’ diabetes drug fakes

More on this story

Editor's picks

Editor's picks

More features